Skip to content
BiologicalX

Comparison

DHEA vs Thymosin Alpha-1

Side-by-side of DHEA and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

DHEA

  • Adrenal androgen precursor; serum DHEA-S declines progressively after the third decade of life
  • OTC dietary supplement in US under DSHEA 1994; prescription in EU, UK, Canada, Australia
  • FDA approved as Intrarosa (6.5 mg vaginal insert) for postmenopausal dyspareunia in 2016
  • Acts as tissue-specific prohormone converted intracrinologically to testosterone and estrogens
  • Best evidence: adrenal insufficiency replacement and vaginal atrophy; weaker on cognition and longevity
  • WADA banned in competitive sport; banned in NCAA, MLB, NFL, IOC settings

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute DHEA Thymosin Alpha-1
Category hormone peptide
Also known as dehydroepiandrosterone, prasterone, Intrarosa Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 12 2
Typical dose (mg) 25 1.6
Dosing frequency daily, typically morning 2x weekly
Routes oral, vaginal, topical subcutaneous, intramuscular
Onset (hr) 1 24
Peak (hr) 1 168
Molecular weight 288.42 3108.32
Molecular formula C19H28O2 C129H215N33O55
Mechanism Steroid prohormone converted intracrinologically to testosterone and estrogens in target tissues; also exerts direct effects via sigma-1 receptor, GABA-A modulation, and glucocorticoid receptor interaction. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status OTC supplement in US (DSHEA 1994); prescription in EU, UK, Canada, Australia Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status banned unknown
DEA / Rx OTC supplement in US (not scheduled); Rx in EU, UK, Canada, Australia Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Contraindicated in pregnancy Not recommended; insufficient data
CAS 53-43-0 62304-98-7
PubChem CID 5881 16130571
Wikidata Q411733 Q913854

Safety profile

DHEA

Common side effects

  • acne
  • oily skin
  • hirsutism (women)
  • gynecomastia (men, higher doses)
  • irritability
  • insomnia

Contraindications

  • hormone-sensitive cancer (breast, ovarian, prostate)
  • active liver disease
  • uncontrolled lipid disorder
  • pregnancy and lactation

Interactions

  • warfarin: case reports of altered INR; monitor(moderate)
  • estrogens (HRT): additive estrogenic effect via conversion; monitor(moderate)
  • insulin: may improve insulin sensitivity slightly; monitor glucose(minor)
  • anastrozole: may reduce DHEA-derived estrogen; clinical relevance unclear(minor)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

DHEA comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.

  • If your priority is hormonal optimization, pick DHEA.
  • If your priority is healthspan extension, pick DHEA.
  • If your priority is immune support, pick Thymosin Alpha-1.
  • If your priority is post-training recovery, pick Thymosin Alpha-1.

Edge case: If you want to avoid Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List, DHEA is the more accessible choice.

Default choice: DHEA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between DHEA and Thymosin Alpha-1?

DHEA and Thymosin Alpha-1 differ in category (hormone vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, DHEA or Thymosin Alpha-1?

DHEA half-life is 12 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack DHEA with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper